Regenxbio Positive One Year Data from Phase II Trial of ABBV-RGX-314 for Diabetic Retinopathy

 

• ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events
• Dose level 2 prevented disease progression and reduced vision-threatening events in non-proliferative diabetic retinopathy patients at 1 Year 
  • 70.8% of patients achieved Diabetic Retinopathy Severity Scale improvement vs. 25.0 % in control 
  • 0% of patients worsened ≥2 steps vs. 37.5 % in control
  • ABBV-RGX-314 reduced vision-threatening events by 89% compared to control
• Conference call Monday, November 6, 8:30 a.m. ET

In connection with this announcement, REGENXBIO will host a conference call to discuss the Phase II ALTITUDE trial data with Dr. Barakat and Dr. Peter Kaiser, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine and Cole Eye Institute, and Dr. Pakola on Monday, November 6 at 8:30 a.m. ET. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

Data presented is available on the "Publications" section of the REGENXBIO website at www.regenxbio.com.

https://www.biospace.com/article/releases/regenxbio-presents-positive-one-year-data-from-phase-ii-altitude-trial-of-abbv-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/